| 1 | Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. 2018;50: doi: 10.1038/s12276-018-0115-0 |
| 2 | Neurologische Nebenwirkungen von Checkpoint-Inhibitoren. 2019;90:138 doi: 10.1007/s00115-018-0571-8 |
| 3 | Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. 2019;9: doi: 10.3389/fonc.2019.00396 |
| 4 | Recent advances in localized immunotherapy of skin cancers. 2019;11:443 doi: 10.2217/imt-2018-0139 |
| 5 | CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. 2018;6:105 doi: 10.3390/biomedicines6040105 |
| 6 | Bioactive Nanoparticles for Cancer Immunotherapy. 2018;19:3877 doi: 10.3390/ijms19123877 |
| 7 | MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. 2019;303:223 doi: 10.1016/j.jconrel.2019.04.019 |
| 8 | Learning-accelerated discovery of immune-tumour interactions. 2019; doi: 10.1039/C9ME00036D |
| 9 | Checkpoint inhibitors: What gastroenterologists need to know. 2018;24:5433 doi: 10.3748/wjg.v24.i48.5433 |
| 10 | Editorial. 2019;12:3 doi: 10.1111/ors.12402 |
| 11 | Combined strategies for tumor immunotherapy with nanoparticles. 2019; doi: 10.1007/s12094-019-02081-3 |
| 12 | Novel therapeutic strategies for spinal osteosarcomas. 2019; doi: 10.1016/j.semcancer.2019.05.018 |
| 13 | Immunotherapy. 2018;995:131 doi: 10.1007/978-3-030-02505-2_6 |